peptide purity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
=== Recruiting === McCormick was a three-star recruit, and The Oregonian listed him as the #2 football prospect in the state of Oregon upon the completion of the 2015 Oregon high school football season. Prior to his enrollment, McCormick committed to Oregon in February 2015.
This was the seventh time Pakistan has carried out airstrikes in Afghanistan since the Afghan Taliban took over in August 2021. The Taliban-led Afghan government condemned the strikes as a "blatant violation of Afghanistan's territorial integrity" and a breach of international law, stating that they hit civilian homes, a religious seminary, and other civilian structures, killing at least 18 people (including women and children) and leaving others missing under rubble. In addition, one family in Girdi Kas lost 18 of 23 members, and additional casualties were reported in Paktika. Afghan officials vowed an "appropriate and measured response" at a suitable time. On 24 February, the hostilities resumed as both countries exchanged fire along their borders while both sides blamed each other for provocations. Zabihullah Noorani, head of the Afghan information department in eastern Nangarhar, stated that Pakistani troops carried out the first shots in the Shahkot area near the border. Pakistan claimed that its forces retaliated in response to a mortar and rocket from Afghanistan on Jarobi Kandao area of the Zakhakhel tehsil, with skirmishes later spreading to Wragha, Maro Sar, Shahkot and Zakhakhel. Pakistan also claimed that Taliban initiated 'unprovoked firing" in Torkham and Tirah. Both light and heavy weapons were used in skirmishes in Nazyan and Achin. An Afghan militant was killed during an infiltration attempt across the border in North Waziristan District.
== Treatment == Unless otherwise demonstrated, nerve injuries are commonly irreversible, and therefore complete treatment is rather difficult, though still possible and hence lifelong management of disabilities arising due to nerve injuries is necessary.
Sources: en.wikipedia.org
== Definition == Natural uranium contains about 0.72% 235U. Depleted uranium has lower mass fractions—up to three times less—of 235U and 234U than natural uranium. Since 238U has a much longer half-life than the lighter isotopes, DU is about 40% less radioactive than natural uranium. Most of the alpha radiation comes from 238U and 234U whereas beta radiation comes from decay products 234Th and 234Pa that are formed within a few weeks. The United States Nuclear Regulatory Commission (NRC) defines depleted uranium as uranium with a percentage of the 235U isotope that is less than 0.711% by weight (see 10 CFR 40.4). The military specifications designate that the DU used by the U.S. Department of Defense (DoD) contain less than 0.3% 235U. In actuality, DoD uses only DU that contains approximately 0.2% 235U.
== Role in cancer == Most germline or somatic mutations in the MEN1 gene predict truncation or absence of encoded menin resulting in the inability of MEN1 to act as a tumor suppressor gene. Such mutations in MEN1 have been associated with defective binding of encoded menin to proteins implicated in genetic and epigenetic mechanisms. Menin is a 621 amino acid protein associated with insulinomas which acts as an adapter while also interacting with partner proteins involved in vital cell activities such as transcriptional regulation, cell division, cell proliferation, and genome stability. Insulinomas are neuroendocrine tumors of the pancreas with an incidence of 0.4 % which usually are benign solitary tumors but 5-12 % of cases have distant metastasis at diagnosis. These familial MEN-1 and sporadic tumors may arise either due to loss of heterozygosity or the chromosome region 11q13 where MEN1 is located, or due to presence of mutations in the gene. MEN1 mutations comprise mostly frameshift deletions or insertions, followed by nonsense, missense, splice-site mutations and either part or complete gene deletions resulting in disease pathology. Frameshift and nonsense mutations result in a supposed inactive and truncated menin protein while splice-site mutations result in incorrectly spliced mRNA. Missense mutations of MEN1 are especially important as they result in a change to crucial amino acids needed in order to bind and interact with other proteins and molecules.
=== With feline features === Gopaitioshah – The Persian Gopat or Gopaitioshah is another creature that is similar to the Sphinx, being a winged bull or lion with human face. The Gopat have been represented in ancient art of Iran since late second millennium BC, and was a common symbol for dominant royal power in ancient Iran. Gopats were common motifs in the art of Elamite period, Luristan, North and North West region of Iran in Iron Age, and Achaemenid art, and can be found in texts such as the Bundahishn, the Dadestan-i Denig, the Menog-i Khrad, as well as in collections of tales, such as the Matikan-e yusht faryan and in its Islamic replication, the Marzubannama. Löwenmensch figurine – The 32,000-year-old Aurignacian Löwenmensch figurine, also known as "lion-human", is the oldest known anthropomorphic statue, discovered in the Hohlenstein-Stadel, a German cave in 1939. Manticore – The Manticore (Early Middle Persian: Mardyakhor or Martikhwar, "man-eater") is a Persian legendary hybrid creature and another similar creature to the sphinx. Narasimha – Narasimha ("human-lion") is an incarnation (Avatara) of Vishnu in Hinduism in the Dashavatara of Vishnu who takes the form of half-man/half-Asiatic lion, having a human torso and lower body, but with a lion-like face and claws and in this avatara, Vishnu killed Hiranyakashipu as Narashima and saved the world from chaos in Hindu Mythology. Urmahlullu – Lion-centaurs, represented as sphinxes with arms, are attested in ancient Assyria as Urmahlullu, having a lion body below the waist and a human body above the waist.
Pre-adipocytes are undifferentiated fibroblasts that can be stimulated to form adipocytes. Studies have shed light into potential molecular mechanisms in the fate determination of pre-adipocytes although the exact lineage of adipocyte is still unclear. The variation of body fat distribution resulting from normal growth is influenced by nutritional and hormonal status dependent on intrinsic differences in cells found in each adipose depot. Mesenchymal stem cells can differentiate into adipocytes, connective tissue, muscle or bone. The precursor of the adult cell is termed a lipoblast, and a tumor of this cell type is known as a lipoblastoma.
Sources: en.wikipedia.org
congressman from New York George Izard* (1793), general, politician; second governor of the Territory of Arkansas James Parker (1793), U.S. congressman from New Jersey Peter A. Jay (1794), son of Chief Justice John Jay; member of New York State Assembly and Recorder of New York City Cyrus King (1794), U.S. congressman from Massachusetts John Ferguson (1795), mayor of New York City Daniel D. Tompkins (1795), vice president of the United States; governor of New York Rensselaer Westerlo (1795), U.S. congressman from New York Edward Philip Livingston (1796), member of the New York State Senate, great-great-grandfather of Eleanor Roosevelt Rudolph Bunner (1798), U.S. congressman from New York John M. Bowers (1800s), U.S. congressman from New York Gulian C. Verplanck (1801), U.S. congressman from New York and chairman of the United States House Committee on Ways and Means Gouverneur Kemble (1803), U.S. congressman from New York and founder of the West Point Foundry John L. Lawrence (1803), member of New York State Assembly and New York State Senate Alpheus Sherman (1803), member of New York State Senate James Alexander Hamilton (1805), son of Alexander Hamilton, soldier, acting United States secretary of state under president Andrew Jackson, and U.S. attorney for the Southern District of New York 1829–1834 Edmund H. Pendleton (1805), U.S. congressman from New York, great-nephew of Edmund Pendleton, first chief justice of Virginia Samuel B.
Upgrading an existing 35-kilowatt generator to a brand new 200-kilowatt unit. Completely gutting and refinishing three laboratory spaces, which included: Removal of original built-in casework and replacement with modular units that can be moved to fit changing workflows. Replacement of fluorescent lighting with high-efficiency LED panels. Replacement of flaking epoxy floors with brand-new laboratory-grade finish. Addition of auxiliary cooling units for each space to provide the humidity and temperature control required to perform high complexity assays. Installation of new dedicated circuits tied into backup power via a new generator. Restoration and upgrade of the existing HVAC system The new lab was completed on August 1 and became operational on August 24.
=== Phase 1 === NTX-1955 (RO-7308480) – γ1 subunit-containing GABAA receptor positive allosteric modulator SPT-320 (LYT-320) – agomelatine prodrug (melatonin receptor agonist and weak serotonin 5-HT2B and 5-HT2C receptor antagonist)
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.